Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-03-11 00:00:00 ET · period of report 2022-03-10 · accession 0000899243-22-010762 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-03-11 | 2022-03-10+ | KLRS | Hallal David | Dir, 10% | S - Sale | $7.48 | -65.7K | 2.15M | -3% | -$491.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-10 | S | D | 40,481 | $7.55 | 2,173,085 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.27 to $7.83. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2022-03-11 | S | D | 25,244 | $7.37 | 2,147,841 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.18 to $7.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request |